Skip to main content
SpringerLink
Log in

Klinische Wirksamkeit von Famotidin: Ein Überblick

  • Conference paper
Famotidin heute

  • 17 Accesses

Zusammenfassung

Der Histamin-H2-Rezeptorantagonist Famotidin wurde 1985 in Japan zur Behandlung des peptischen Ulcusleidens eingeführt. Inzwischen ist er in vielen europäischen Ländern sowie in den Vereinigten Staaten von Amerika verfügbar. Die folgende Übersicht beschäftigt sich mit den Ergebnissen international durchgeführter Studien zur Wirksamkeit von Famotidin bei verschiedenen säurebedingten Erkrankungen des oberen Gastrointestinaltraktes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Gitlin N, McCullough A J, Smith J L, Mantell G, Berman R (1987): A multicenter, double-blind, randomized, placebocontrolled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 92, 48 – 53

    PubMed  CAS  Google Scholar 

  2. Bianchi-Porro G, Dicenta C, Cook Th, Humphries T J (1987): Review of unextensive world-wide study of a new H2-receptor antagonist famotidine as compared to ranitidine in the treatment of acute duodenal ulcer. Journ of Clin Gastronoenterol 9 (Suppl 2), 14 – 18

    Article  Google Scholar 

  3. Rodrigo L, Viver J, Conchillo F, Barrio E et al (1987): A multicentric, randomized, double-blind study comparing famotidine versus Cimetidine in the treatment of active duodenal ulcer disease. Ital J Gastroenterol 19 [Suppl 3]: 67

    Google Scholar 

  4. Pajares J, Pique J, Guardia J et al (1987): A multicenter, randomized, double-blind study comparing famotidine versus ranitidine in the treatment of active duodenal ulcer disease. Ital J Gastroenterol 19 [Suppl 3]: 68

    Google Scholar 

  5. Dobrilla G, De Pretis G, Piazzi L et al (1987): Comparison of oncedaily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. Scand J Gastroenterol 22 [Suppl 134]: 21 – 28

    Article  Google Scholar 

  6. Mann S G, Cottrell J (1987): Single night-time dosis of famotidine and Cimetidine in duodenal ulcer: A double-blind comparative study. Ital J Gastroenterol 19 [Suppl 3]: 68

    Google Scholar 

  7. Texter E C, Navab F, Mantell G, Berman R (1986): Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study. Amer J Med 81 [Suppl 4B]: 25 – 32

    Article  PubMed  Google Scholar 

  8. Stadelmann O, Groh E (1986): Rezidivprophylaxe der Ulcus-duodeni- Erkrankung mit Famotidin. In: Simon B, Bianchi Porro G, Dammann H G, (Hrsg) Famotidin. Ein Fortschritt in der Therapie säurebedingter Erkrankungen. Thieme, Stuttgart, S, 71 - 76

    Google Scholar 

  9. Dammann H G, Walter T. A, Hentschel E, Müller P, Simon B (1987): Famotidine: Proven once-a-day treatment for gastric ulcer. Scand J Gastroenterol 22 [Suppl 134]: 29 – 33

    Article  Google Scholar 

  10. Humphries T et al (1988): Clinical experience with famotidine 40 mg at night in the acute treatment of benign gastric ulcer. United States Data (in press)

    Google Scholar 

  11. Martin L, Ruiz-Capellan R, Dicenta C (1987): A randomized, doubleblind study comparing famotidine with ranitidine in the treatment of benign gastric ulcers. Ital J Gastroenterol 19 [Suppl 3], 66

    Google Scholar 

  12. Rodrigo M, Castro J, Pleguezuelo J et al (1987): A randomized doubleblind study comparing famotidine with cimetidine in the treatment f benign gastric ulcers. Ital J Gastroenterol 19 [Suppl 3]: 66

    Google Scholar 

  13. Howard J M, Collen M J, Cherner J A et al (1985): Famotidine: An effective H2-antagonist for the therapy of Zollinger Ellison syndrome (ZES). Gastroenterology 88: 1026 – 1033

    PubMed  CAS  Google Scholar 

  14. Sekiguchi T, Nishioka T, Kogure M et al (1987): Once-daily administration of famotidine for reflux esophagitis. Scand J Gastroenterol 22 [Suppl 134]: 51–54

    Article  Google Scholar 

  15. Saigenji K, Fukotomi H, Nakazawa S (1987): Famotidine: Postmarketing clinical experience. Scand J Gastroenterol 22 [Suppl 134]: 34 – 40

    Article  Google Scholar 

Download references

Authors
  1. B. Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-G. Dammann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Simon, B., Dammann, HG., Müller, P. (1989). Klinische Wirksamkeit von Famotidin: Ein Überblick. In: Famotidin heute. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73807-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73807-4_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73808-1

  • Online ISBN: 978-3-642-73807-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation